# Phosphoglucose isomerase directs the inflammatory response, calcium influx and fibroblast migration in keloids

**Authors:** Ying-Yi Lu, Chun-Ching Lu, Wei-Ting Wang, Chieh-Hsin Wu

PMC · DOI: 10.1080/20565623.2026.2615968 · Future Science OA · 2026-01-20

## TL;DR

This study shows that phosphoglucose isomerase (PGI) controls inflammation, calcium levels, and fibroblast movement in keloids, suggesting PGI inhibition could be a treatment.

## Contribution

First study to show PGI regulates keloid fibroblast migration via calcium influx and inflammation.

## Key findings

- PGI expression is upregulated in keloid tissues and fibroblasts.
- Blocking PGI reduces fibroblast migration and inflammatory signaling.
- PGI regulates fibrotic activity and calcium influx in keloid fibroblasts.

## Abstract

Keloids are regarded as an inflammatory skin disease with altered metabolic demands. Calcium ions are known to regulate cell movement. Phosphoglucose isomerase (PGI) not only balances glucose metabolism but also acts as a multifunctional cytokine, as those calcium ions do. Here, for the first time, we aimed to explore the intracellular calcium level controlled by PGI in keloid fibroblasts (KFs) and normal fibroblasts (NFs). In addition, whether PGI regulates the biological functions of KFs via the inflammatory status was investigated.

The inflammatory status, fibrotic activity, and migration ability of KFs and NFs were evaluated via RT–PCR, western blot analysis, and scratch assay. We inhibited PGI with erythrose 4-phosphate (ER4P) to determine whether PGI regulates KF migration.

The upregulation of PGI expression was measured in both KFs and keloid tissues. Suppressing PGI inhibited SMA and type I collagen expression, and cell migration in KFs. Indeed, PGI regulated inflammation and calcium influx in KFs.

Our study is the first to show that PGI regulates the migration of KFs via a calcium influx-dependent inflammatory response and that blocking PGI might be a therapeutic strategy for keloids.

Keloids are a pathological scar with altered metabolic demands. With increasing capacity to synthesize collagen, keloid fibroblasts continuously have high metabolic demands. To overcome energetic consumption, keloid fibroblasts undergo metabolic reprogramming with reduced oxidative phosphorylation and augmented glycolysis.Keloids are also regarded as an inflammatory skin disease. Excessive and prolonged inflammatory responses tend to lead to the development of pathological scars. The inflammation intensity is positively associated with the scar size.Free calcium ions are important for cellular activities including cell proliferation, differentiation, movement and death.Phosphoglucose isomerase (PGI) not only balances glucose metabolism but also acts as a multifunctional cytokine to induce cell proliferation, differentiation, or metastasis.PGI expression was increased in hyperfibrotic regions in keloid tissues and keloid fibroblasts (KFs).PGI controls fibrotic activity in KFs by regulating the synthesis of α-SMA, collagen I and the release of TGF-β.PGI regulated inflammatory activity in KFs such as IL-33, NK-κB, TNF-α, IL-1 and IL-6.Blocking PGI decreased enhanced cytosolic Ca2+ signaling in KFs.Blocking PGI inhibits fibroblast migration in KFs.Our study is the first to show that PGI regulates the migration of KFs via a calcium influx-dependent inflammatory response. Blocking PGI might be a therapeutic strategy for keloids.

Keloids are a pathological scar with altered metabolic demands. With increasing capacity to synthesize collagen, keloid fibroblasts continuously have high metabolic demands. To overcome energetic consumption, keloid fibroblasts undergo metabolic reprogramming with reduced oxidative phosphorylation and augmented glycolysis.

Keloids are also regarded as an inflammatory skin disease. Excessive and prolonged inflammatory responses tend to lead to the development of pathological scars. The inflammation intensity is positively associated with the scar size.

Free calcium ions are important for cellular activities including cell proliferation, differentiation, movement and death.

Phosphoglucose isomerase (PGI) not only balances glucose metabolism but also acts as a multifunctional cytokine to induce cell proliferation, differentiation, or metastasis.

PGI expression was increased in hyperfibrotic regions in keloid tissues and keloid fibroblasts (KFs).

PGI controls fibrotic activity in KFs by regulating the synthesis of α-SMA, collagen I and the release of TGF-β.

PGI regulated inflammatory activity in KFs such as IL-33, NK-κB, TNF-α, IL-1 and IL-6.

Blocking PGI decreased enhanced cytosolic Ca2+ signaling in KFs.

Blocking PGI inhibits fibroblast migration in KFs.

Our study is the first to show that PGI regulates the migration of KFs via a calcium influx-dependent inflammatory response. Blocking PGI might be a therapeutic strategy for keloids.

## Linked entities

- **Genes:** BGN (biglycan) [NCBI Gene 633], SMN1 (survival of motor neuron 1, telomeric) [NCBI Gene 6606], TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040], IL33 (interleukin 33) [NCBI Gene 90865], TNF (tumor necrosis factor) [NCBI Gene 7124], IL1A (interleukin 1 alpha) [NCBI Gene 3552], IL6 (interleukin 6) [NCBI Gene 3569]
- **Chemicals:** erythrose 4-phosphate (PubChem CID 122357), Ca2+ (PubChem CID 271)

## Full-text entities

- **Genes:** TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, IL10 (interleukin 10) [NCBI Gene 3586] {aka CSIF, GVHDS, IL-10, IL10A, TGIF}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, IL33 (interleukin 33) [NCBI Gene 90865] {aka C9orf26, DVS27, IL1F11, NF-HEV, NFEHEV}, CCN2 (cellular communication network factor 2) [NCBI Gene 1490] {aka CTGF, HCS24, IBP-8, IGFBP8, KMD, NOV2}, POTEF (POTE ankyrin domain family member F) [NCBI Gene 728378] {aka A26C1B, POTE2alpha, POTEACTIN}, GPI (glucose-6-phosphate isomerase) [NCBI Gene 2821] {aka AMF, CNSHA4, GNPI, NLK, PGI, PHI}, ACTA1 (actin alpha 1, skeletal muscle) [NCBI Gene 58] {aka ACTA, ASMA, CFTD, CFTD1, CFTDM, CMYO2A}, KCNN4 (potassium calcium-activated channel subfamily N member 4) [NCBI Gene 3783] {aka DHS2, IK, IK1, IKCA1, KCA4, KCa3.1}, VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}, VIM (vimentin) [NCBI Gene 7431], IL1A (interleukin 1 alpha) [NCBI Gene 3552] {aka IL-1 alpha, IL-1A, IL1, IL1-ALPHA, IL1F1}, CANX (calnexin) [NCBI Gene 821] {aka CNX, IP90, P90}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, IL4 (interleukin 4) [NCBI Gene 3565] {aka BCGF-1, BCGF1, BSF-1, BSF1, IL-4}, HK1 (hexokinase 1) [NCBI Gene 3098] {aka CNSHA5, HK, HK1-ta, HK1-tb, HK1-tc, HKD}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, IL13 (interleukin 13) [NCBI Gene 3596] {aka IL-13, P600}, ATP2A3 (ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 3) [NCBI Gene 489] {aka SERCA3}, SMN1 (survival of motor neuron 1, telomeric) [NCBI Gene 6606] {aka BCD541, GEMIN1, SMA, SMA1, SMA2, SMA3}
- **Diseases:** cancer metastasis (MESH:D009369), fibrosis (MESH:D005355), rheumatoid arthritis (MESH:D001172), fibrosarcoma (MESH:D005354), scars (MESH:D002921), tenderness (MESH:D063806), glioma (MESH:D005910), idiopathic pulmonary fibrosis (MESH:D054990), Keloids (MESH:D007627), Inflammatory (MESH:D007249), pruritus (MESH:D011537), fibrotic lesions (MESH:D009059), colorectal cancer (MESH:D015179), inflammatory skin disease (MESH:D012871), proinflammatory factors (MESH:D005171), cutaneous trauma (MESH:D014947), metastasis (MESH:D009362), epidermal cysts (MESH:D004814), melanocytic nevus (MESH:D009508)
- **Chemicals:** glucose-6phosphate (MESH:D019298), Abcam (-), glucose (MESH:D005947), DAPI (MESH:C007293), probenecid (MESH:D011339), Calcium (MESH:D002118), Alexa Fluor  488 (MESH:C000711379), TRIzol (MESH:C411644), SDS (MESH:D012967), fructose-6 phosphate (MESH:C027618), water (MESH:D014867), paraffin (MESH:D010232), CO2 (MESH:D002245), PBS (MESH:D007854), ER4P (MESH:C026959), hematoxylin (MESH:D006416), PVDF (MESH:C024865), ATP (MESH:D000255), Fluo-4 (MESH:C409648), paraformaldehyde (MESH:C003043), Triton X-100 (MESH:D017830), pentose phosphate (MESH:D010428)
- **Species:** Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090]
- **Cell lines:** HEK293 — Homo sapiens (Human), Transformed cell line (CVCL_0045), Fibroblasts — Mus musculus (Mouse), Spontaneously immortalized cell line (CVCL_0594), HT1080 — Homo sapiens (Human), Fibrosarcoma, Cancer cell line (CVCL_0317), KFs — Homo sapiens (Human), Finite cell line (CVCL_3730)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12826743/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12826743/full.md

## References

59 references — full list in the complete paper: https://tomesphere.com/paper/PMC12826743/full.md

---
Source: https://tomesphere.com/paper/PMC12826743